65,437 trials
Hyponatremia · Euvolemia · Hypervolemia
Primary: Number and Severity of Infusion Site Reactions (ISRs) Using a Modified ISR Reporting Scale for Phlebitis and Infiltration in Patients Treated With Dose Regimen 1 and…
Allergic Asthma
Primary: Change in Logarithmically Transformed (log2) Allergen PC15 Concentration (Allergen Concentration Required to Evoke a 15% Decrease in FEV1) — 1.15; 1.85; 0.36…
Hypercholesterolemia
Primary: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment — -41.69; -46.83; -49.10; -7.53 percent change of…
Hypercholesterolemia
Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 — -39.5; -54.2; -46.6; -59.1 Percent change in LDL-C — p=<0.001
Contraception
Primary: Number of Days of Unscheduled Blood Loss - Cycle 1 — 1.9; 2.0 Days — p=0.9698
Cardiovascular Diseases · Heart Diseases
Primary: Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events — 3; 4; 4; 3…
Osteoarthritis, Knee
Primary: Incidence of Nausea and Vomiting — 25; 32 participants — p=<0.05
Chronic Hepatitis B
Primary: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell…
Chronic Hepatitis B
Primary: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell…
Gastroesophageal Reflux
Primary: Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS) — -0.89; 0.02; -0.47; -1.11 units on scale — p=<0.001
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Guanfacine — 2.6; 2.7 ng/ml
Rabies
Primary: Rabies Virus Neutralizing Antibody Concentrations on Day 14. — 3.1; 3.3 IU/mL
GERD
Primary: Change From Baseline in Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring — -28.01; -24.79 Mean Number of Events
Breast Neoplasms
Primary: Percentage of Participants With Overall Confirmed Objective Disease Response — 36.8 percentage of participants
Diabetes Mellitus
Primary: Number of Participants Rated Successful (<=3) at Performing Specific Tasks — 50; 50; 50; 50 participants